Aron Stein

Aron has Over 35 years of product development experience in the

pharmaoeutical and biotecnnology industry, naving responsibilty Tor muitiple

drug approvals at both large and small companies. Prior to joining Intellia, Dr.

Stein was the Vice President of Global Regulatory Affairs of Sangamo

Therapeutics, where he was responsible for the development aind

implementation of global regulatory strategies for all gene and cellular

therapies.

At Intellia, Aron prOvides the vision, strategic direction and corporate

regulatory approach for all company products. He is responsible for the

analysis and evaluation of U.S. and global regulatory requirements, as well as

provides strategic insights to translate regulatory requirements into practical,

Workable global plans for timely and scientifically valid regulatory

submissions. He is a toxicologist by training and received his Ph.D. from Texas

A&M University and was a NIEHS postdoctoral fellow at the University of Kansas

Medical Center.